PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
11248451-2	2001	The highest scores of SP-A staining, with dense granular deposits (aggregates) in the intra-alveolar space, were observed in fatalities from pancuronium bromide (muscle relaxant) injection and petroleum (butane) gas inhalation.	Pancuronium	141-160	surfactant protein A2	Homo sapiens	22-26
10960373-2	2000	The inhibition of norepinephrine transporter (NET) in the sympathetic nervous system may partly account for the stimulatory actions of pancuronium.	Pancuronium	135-146	solute carrier family 6 member 2	Bos taurus	18-44
10960373-13	2000	Pancuronium may affect the sympathetic nervous system by inhibiting the activity of the presynaptic norepinephrine transporter at clinically relevant concentrations.	Pancuronium	0-11	solute carrier family 6 member 2	Bos taurus	100-126
10960409-8	2000	The plasma cholinesterase activity was measured before induction for all patients and 3 min after the injection of pancuronium for Groups PM1 and PM2.	Pancuronium	115-126	transmembrane protein 11	Homo sapiens	138-141
10960409-9	2000	The plasma cholinesterase activity was decreased by 16% and 33% after pancuronium administration in Groups PM1 and PM2, respectively.	Pancuronium	70-81	butyrylcholinesterase	Homo sapiens	11-25
10960409-9	2000	The plasma cholinesterase activity was decreased by 16% and 33% after pancuronium administration in Groups PM1 and PM2, respectively.	Pancuronium	70-81	transmembrane protein 11	Homo sapiens	107-110
9260930-10	1997	In voltage-clamped hOCT2-expressing oocytes, inward currents were induced by superfusion with MPP, TEA, choline, quinine, d-tubocurarine, pancuronium, and cyanine863.	Pancuronium	138-149	solute carrier family 22 member 2	Homo sapiens	19-24
14564607-1	2000	PURPOSE: The kinetics of the inhibition of human plasma cholinesterase (ChE) and erythrocyte acetylcholinesterase (AChE) by alcuronium, atracurium, d-tubocurarine, pancuronium, pipecuronium, and vecuronium were studied in blood drawn from 35 surgical patients.	Pancuronium	164-175	butyrylcholinesterase	Homo sapiens	56-70
14564607-1	2000	PURPOSE: The kinetics of the inhibition of human plasma cholinesterase (ChE) and erythrocyte acetylcholinesterase (AChE) by alcuronium, atracurium, d-tubocurarine, pancuronium, pipecuronium, and vecuronium were studied in blood drawn from 35 surgical patients.	Pancuronium	164-175	acetylcholinesterase (Cartwright blood group)	Homo sapiens	93-113
14564607-1	2000	PURPOSE: The kinetics of the inhibition of human plasma cholinesterase (ChE) and erythrocyte acetylcholinesterase (AChE) by alcuronium, atracurium, d-tubocurarine, pancuronium, pipecuronium, and vecuronium were studied in blood drawn from 35 surgical patients.	Pancuronium	164-175	acetylcholinesterase (Cartwright blood group)	Homo sapiens	115-119
14564607-6	2000	The apparent inhibition constants (K(i)) of pancuronium (8.72 x 10(-8) M) and vecuronium (3.53 x 10(-7) M) for plasma ChE inhibition were lower than that of neostigmine (7.36 x 10(-7) M), whereas those of the six nondepolarizing NMBAs for erythrocyte AChE were markedly higher than that of neostigmine.	Pancuronium	44-55	butyrylcholinesterase	Homo sapiens	118-121
14564607-6	2000	The apparent inhibition constants (K(i)) of pancuronium (8.72 x 10(-8) M) and vecuronium (3.53 x 10(-7) M) for plasma ChE inhibition were lower than that of neostigmine (7.36 x 10(-7) M), whereas those of the six nondepolarizing NMBAs for erythrocyte AChE were markedly higher than that of neostigmine.	Pancuronium	44-55	acetylcholinesterase (Cartwright blood group)	Homo sapiens	251-255
14564607-8	2000	The inhibitory potencies of pancuronium and vecuronium for plasma ChE were larger than that of neostigmine, whereas those of the six nondepolarizing NMBAs for erythrocyte AChE were markedly lower than that of neostigmine.	Pancuronium	28-39	butyrylcholinesterase	Homo sapiens	66-69
14564607-9	2000	The rank order of relative potency for plasma ChE was pancuronium > vecuronium > pipecuronium > alcuronium > d-tubocurarine > atracurium.	Pancuronium	54-65	butyrylcholinesterase	Homo sapiens	46-49
9689393-12	1998	Only Pancuronium caused a significant increase in heart rate (53 +/- 11 to 61 +/- 15 min-1) whereas cardiac index and mean arterial pressure did not change significantly.	Pancuronium	5-16	CD59 molecule (CD59 blood group)	Homo sapiens	85-90
9260018-13	1997	CONCLUSION: Residual neuromuscular block, TOF ratio < 0.7, is common after cardiac surgery but the incidence is less when pancuronium is replaced by rocuronium.	Pancuronium	125-136	FEZ family zinc finger 2	Homo sapiens	42-45
8732292-5	1996	The Ca2+ response evoked by carbachol (10 microM) was completely blocked by the nAChR antagonist, pancuronium (3 microM), but was not affected by the muscarinic antagonist, atropine (3 microM), or under conditions when Ca2+ entry was blocked by La3+ (50 microM) or diltiazem (10 microM).	Pancuronium	98-109	cholinergic receptor, nicotinic, alpha polypeptide 7	Mus musculus	80-85
9052321-8	1997	The mivacurium infusion requirement for the group receiving the pancuronium supplementation was 2.77 +/- 1.38 micrograms.kg-1.min-1 (mean +/- SD), which represented a 49% decrease compared with the group that used mivacurium alone which required an infusion rate of 5.43 +/- 1.85 micrograms.kg-1.min-1.	Pancuronium	64-75	CD59 molecule (CD59 blood group)	Homo sapiens	126-131
9052321-8	1997	The mivacurium infusion requirement for the group receiving the pancuronium supplementation was 2.77 +/- 1.38 micrograms.kg-1.min-1 (mean +/- SD), which represented a 49% decrease compared with the group that used mivacurium alone which required an infusion rate of 5.43 +/- 1.85 micrograms.kg-1.min-1.	Pancuronium	64-75	CD59 molecule (CD59 blood group)	Homo sapiens	296-301
8889423-4	1996	The prolonged effect of mivacurium may have been because of inhibition of plasma cholinesterase by pancuronium.	Pancuronium	99-110	butyrylcholinesterase	Homo sapiens	81-95
7643875-7	1995	In the patient controls, pancuronium 4 mg induced a severe neuromuscular block but not with 1 and 2 mg. Pancuronium dosages necessary to reverse severe OP-induced neuromuscular blockade produce a neuromuscular block when AChE activity is normal.	Pancuronium	25-36	acetylcholinesterase (Cartwright blood group)	Homo sapiens	221-225
7643875-7	1995	In the patient controls, pancuronium 4 mg induced a severe neuromuscular block but not with 1 and 2 mg. Pancuronium dosages necessary to reverse severe OP-induced neuromuscular blockade produce a neuromuscular block when AChE activity is normal.	Pancuronium	104-115	acetylcholinesterase (Cartwright blood group)	Homo sapiens	221-225
7484025-9	1995	This was highly significantly different from the estimated 50% NMB if only additivity exists between mivacurium and pancuronium (P = 0.0001).	Pancuronium	116-127	neuromedin B	Homo sapiens	63-66
7486299-2	1995	During induction, whereas the basal heart rate was at 30-35 b.min-1, occurred an episode of bidirectional ventricular tachycardia probably induced by the administration of pancuronium.	Pancuronium	172-183	CD59 molecule (CD59 blood group)	Homo sapiens	62-67
7905936-5	1994	There was significant higher T1/Tc and T1/T4 ratio for the hypothenar muscle than for the thenar muscle within 60 minutes from pancuronium administration.	Pancuronium	127-138	CD5 molecule	Homo sapiens	29-34
8135388-12	1994	After pancuronium and atracurium, PTC1 and T1OO recovered before T1AP (P < 0.001).	Pancuronium	6-17	patched 1	Homo sapiens	34-38
1897345-0	1991	Pretreatment with pancuronium before suxamethonium administration in patients heterozygous for the usual and the atypical plasma cholinesterase gene.	Pancuronium	18-29	butyrylcholinesterase	Homo sapiens	129-143
7916437-0	1994	Cholinesterase inhibition by vecuronium and pancuronium in human airways.	Pancuronium	44-55	butyrylcholinesterase	Homo sapiens	0-14
1419447-2	1992	The technique was used successfully to investigate transfer of pancuronium to the cerebral CSF compartment in pigs.	Pancuronium	63-74	colony stimulating factor 2	Sus scrofa	91-94
1683184-4	1991	The infusion rates of vecuronium, atracurium, and pancuronium were adjusted to achieve a T1/Tc ratio of between 0.02 and 0.10 (T1 = height of first twitch, Tc = height of control twitch).	Pancuronium	50-61	CD5 molecule	Homo sapiens	89-94
1978211-1	1990	Plasma cholinesterase activity was measured in patients following administration of pancuronium and vecuronium at dosages of 0.1 mg/kg.	Pancuronium	84-95	butyrylcholinesterase	Homo sapiens	7-21
1681665-6	1991	In addition, pancuronium, but not vecuronium, also slightly increased the IgE levels (by 5.9% of control IgE).	Pancuronium	13-24	immunoglobulin heavy constant epsilon	Homo sapiens	74-77
1681665-6	1991	In addition, pancuronium, but not vecuronium, also slightly increased the IgE levels (by 5.9% of control IgE).	Pancuronium	13-24	immunoglobulin heavy constant epsilon	Homo sapiens	105-108
34269114-6	2021	From the primary screening, we identified a group of 125 compounds that were further confirmed to inhibit BChE activity, including previously reported BChE inhibitors (e.g., bambuterol and rivastigmine) and potential novel BChE inhibitors (e.g., pancuronium bromide and NNC 756), representing diverse structural classes.	Pancuronium	246-265	butyrylcholinesterase	Homo sapiens	106-110
2563317-8	1989	Thirty-two per cent of patients receiving pancuronium received propranolol for heart rates greater than 90 beats.min-1 versus 7% of those who received vecuronium (P approximately 0.01).	Pancuronium	42-53	CD59 molecule (CD59 blood group)	Homo sapiens	113-118
2514612-8	1989	Specific FITC-alpha-BGT binding to the nAChR protein on the optic fibers was inhibited by agonists (e.g., acetylcholine, nicotine, and carbamylcholine) and antagonists (e.g., pancuronium and d-tubocurarine) of the nAChR and was insensitive to high salt concentrations (e.g., 154 mM NaCl).	Pancuronium	175-186	cholinergic receptor nicotinic alpha 4 subunit	Homo sapiens	39-44
3034626-3	1987	The doses producing 50% antagonism (ED50) of the pancuronium-induced neuromuscular block were 0.50, 0.54 and 0.71 mg/kg for LF-14, 2,4-DAP and 4-AP respectively.	Pancuronium	49-60	death associated protein	Homo sapiens	135-138
3059852-7	1988	After the administration of pancuronium (0.15 mg.kg-1), the patients in group P showed a significant increase in heart rate (+ 14 b.min-1), accompanied by an increase in cardiac index (+0.45 l.min-1.m-2).	Pancuronium	28-39	CD59 molecule (CD59 blood group)	Homo sapiens	132-137
3059852-7	1988	After the administration of pancuronium (0.15 mg.kg-1), the patients in group P showed a significant increase in heart rate (+ 14 b.min-1), accompanied by an increase in cardiac index (+0.45 l.min-1.m-2).	Pancuronium	28-39	CD59 molecule (CD59 blood group)	Homo sapiens	193-198
3697814-6	1986	The pancuronium pretreated group presented less variable values of serum myoglobin which, when compared to the control group, had a more significant p value (p less than 0.001) than for d-tubocurarine pretreated group (p = 0.003).	Pancuronium	4-15	myoglobin	Homo sapiens	73-82
6666843-3	1983	During anaesthesia (fentanyl, pancuronium bromide, ventilation with N2O/O2 1: 1) there was a decrease in CI (26%), SI (18%), HR (5,7%), dp/dt (15%) and an increase in TSR (25%) and TPR (32%); Part, PAP, PCWP and PRA remained unchanged.	Pancuronium	30-49	translocated promoter region, nuclear basket protein	Homo sapiens	181-184
4083176-1	1985	On the basis of previous findings that histamine-N-methyltransferase (HMT) activity can be significantly enhanced or inhibited by a number of analogues of histamine and drugs containing dialkylaminoalkyl moieties, we investigated whether the neuromuscular blocking drugs alcuronium, d-tubocurarine, decamethonium, succinylcholine, gallamine and pancuronium each of which contain quaternary ammonium groups, influence the activity of HMT.	Pancuronium	345-356	histamine N-methyltransferase	Homo sapiens	39-68
4083176-1	1985	On the basis of previous findings that histamine-N-methyltransferase (HMT) activity can be significantly enhanced or inhibited by a number of analogues of histamine and drugs containing dialkylaminoalkyl moieties, we investigated whether the neuromuscular blocking drugs alcuronium, d-tubocurarine, decamethonium, succinylcholine, gallamine and pancuronium each of which contain quaternary ammonium groups, influence the activity of HMT.	Pancuronium	345-356	histamine N-methyltransferase	Homo sapiens	70-73
7074408-7	1982	The authors speculate the aminophylline, which is a known inhibitor of the enzyme phosphodiesterase, raised the level of c-AMP and, in turn, the level of acetylcholine at the neuromuscular junction and thus antagonized the blocking effect of pancuronium.	Pancuronium	242-253	cathelicidin antimicrobial peptide	Homo sapiens	121-126
7225266-2	1981	A significant increase in the elimination half-life T 1/2 beta of pancuronium (from 141 to 224 min) and a significant increase in the volume of the peripheral compartment (V2) was found in patients with extrahepatic cholestasis when compared with control patients.	Pancuronium	66-77	interleukin 1 receptor like 1	Homo sapiens	52-62
7287015-0	1981	Differential inhibition of plasma cholinesterase variants using the dibutyrate analogue of pancuronium bromide.	Pancuronium	91-110	butyrylcholinesterase	Homo sapiens	34-48
7287015-1	1981	A steroid, the dibutyrate analogue of pancuronium bromide (9.8 X 10(-8)M), has been used as differential inhibitor in the study of the plasma cholinesterase variants.	Pancuronium	38-57	butyrylcholinesterase	Homo sapiens	142-156
6108807-0	1980	Inhibition of the plasma cholinesterase variants by pancuronium bromide and some of its analogues.	Pancuronium	52-71	butyrylcholinesterase	Homo sapiens	25-39
6928942-3	1980	This, in addition to the patient"s failure to respond to an anticholinesterase agent, led to the belief that the patient had an atypical cholinesterase response to succinylcholine and not one secondary to a decreased production of cholinesterase enzyme from an impaired liver or prolonged paralysis for the nondepolarizing agent, pancuronium.	Pancuronium	330-341	butyrylcholinesterase	Homo sapiens	137-151
855909-2	1977	The inhibition by pancuronium of acetylcholinesterase (AChE) and of plasma cholinesterase (ChE) was investigated in vitro regarding a) the sensitivity of both enzymes; b) the mechanism and constants of inhibition; and c) the relationship between the neuromuscular blocking and the anticholinesterase activity of pancuronium.	Pancuronium	18-29	acetylcholinesterase (Cartwright blood group)	Homo sapiens	33-53
590336-0	1977	Effect of pancuronium bromide on the adrenergic reactivity of the isolated rat vas deferens.	Pancuronium	10-29	arginine vasopressin	Rattus norvegicus	79-82
590336-3	1977	On the other hand, pancuronium bromide (10(-6) to 10(-4) M) produced 1.62- to 2.65-fold increases in the sensitivity of the vas deferens to noradrenaline.	Pancuronium	19-38	arginine vasopressin	Rattus norvegicus	124-127
588391-6	1977	The findings with pancuronium may be a result of its inhibitory effect on serum cholinesterase.	Pancuronium	18-29	butyrylcholinesterase	Homo sapiens	80-94
843975-5	1977	Although pancuronium markedly inhibited serum cholinesterase in vitro (I50=5 X 10(-7) mol) there was only a 10% inhibition of cholinesterase in vivo after pancuronium 0.08 mg/kg.	Pancuronium	9-20	butyrylcholinesterase	Homo sapiens	46-60
855909-2	1977	The inhibition by pancuronium of acetylcholinesterase (AChE) and of plasma cholinesterase (ChE) was investigated in vitro regarding a) the sensitivity of both enzymes; b) the mechanism and constants of inhibition; and c) the relationship between the neuromuscular blocking and the anticholinesterase activity of pancuronium.	Pancuronium	18-29	acetylcholinesterase (Cartwright blood group)	Homo sapiens	55-59
855909-2	1977	The inhibition by pancuronium of acetylcholinesterase (AChE) and of plasma cholinesterase (ChE) was investigated in vitro regarding a) the sensitivity of both enzymes; b) the mechanism and constants of inhibition; and c) the relationship between the neuromuscular blocking and the anticholinesterase activity of pancuronium.	Pancuronium	18-29	butyrylcholinesterase	Homo sapiens	39-53
855909-2	1977	The inhibition by pancuronium of acetylcholinesterase (AChE) and of plasma cholinesterase (ChE) was investigated in vitro regarding a) the sensitivity of both enzymes; b) the mechanism and constants of inhibition; and c) the relationship between the neuromuscular blocking and the anticholinesterase activity of pancuronium.	Pancuronium	18-29	butyrylcholinesterase	Homo sapiens	56-59
855909-4	1977	Pancuronium is a reversible inhibitor of both AChE and ChE.	Pancuronium	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	46-50
855909-4	1977	Pancuronium is a reversible inhibitor of both AChE and ChE.	Pancuronium	0-11	butyrylcholinesterase	Homo sapiens	47-50
855909-9	1977	The inhibition of AChE and ChE is thought to be induced by a reversible binding of pancuronium to the anionic subsite of the active center, thus decreasing the formation of the primary enzyme-substrate complex.	Pancuronium	83-94	acetylcholinesterase (Cartwright blood group)	Homo sapiens	18-22
855909-9	1977	The inhibition of AChE and ChE is thought to be induced by a reversible binding of pancuronium to the anionic subsite of the active center, thus decreasing the formation of the primary enzyme-substrate complex.	Pancuronium	83-94	butyrylcholinesterase	Homo sapiens	19-22
612115-0	1977	Pseudocholinesterase changes in anesthesia using pancuronium.	Pancuronium	49-60	butyrylcholinesterase	Homo sapiens	0-20
612115-5	1977	From these data one may conclude that pancuronium must be carefully given in patients with low level of pseudocholinesterase when other drugs inhibiting the enzyme activity, like succinylcholine, procaine and propanidid, are used.	Pancuronium	38-49	butyrylcholinesterase	Homo sapiens	104-124
984487-0	1976	Serum cholinesterase activity following pancuronium and antagonism with neostigmine or pyridostigmine.	Pancuronium	40-51	butyrylcholinesterase	Homo sapiens	6-20
136679-0	1976	[Serum acetylcholinesterase changes after pancuronium administration].	Pancuronium	42-53	acetylcholinesterase (Cartwright blood group)	Homo sapiens	7-27
136679-3	1976	The enzyme concentrations were lower in those patients that had also received Pancuronium, suggesting a cummulative inhibitory effect on serum acetylcholinesterase.	Pancuronium	78-89	acetylcholinesterase (Cartwright blood group)	Homo sapiens	143-163
1191483-1	1975	Pancuronium causes a powerful  and highly selective inhibition of human serum cholinesterase in vitro.	Pancuronium	0-11	butyrylcholinesterase	Homo sapiens	78-92
1191483-3	1975	Pancuronium, in a concentration of 2.3 x 10(-7) M, caused a 50% inhibition of the enzymatic hydrolysis of acetylcholine, when this substrate was present in a concentration of 10 x 10(-3) M. The same I50 value was also found for a commercial preparation of human serum cholinesterase.	Pancuronium	0-11	butyrylcholinesterase	Homo sapiens	268-282
1191483-5	1975	Pancuronium inhibition of the acetylcholinesterase in human red blood cells and from the electric eel was more than one thousand times weaker.	Pancuronium	0-11	acetylcholinesterase (Cartwright blood group)	Homo sapiens	30-50
1191483-6	1975	Thus pancuronium is one of the most selective inhibitors of serum cholinesterase described so far.	Pancuronium	5-16	butyrylcholinesterase	Homo sapiens	66-80
1191483-7	1975	The in vivo activity of the serum cholinesterase in four patients receiving pancuronium 0.1 mg/kg decreased, during the first 3 min, by 60-80%, from the pre-induction value.	Pancuronium	76-87	butyrylcholinesterase	Homo sapiens	34-48
1191483-9	1975	The tachycardia produced by pancuronium may be related to this selective inhibition of serum cholinesterase.	Pancuronium	28-39	butyrylcholinesterase	Homo sapiens	93-107
27146658-10	2016	CONCLUSION: Pancuronium microinjection into the lateral ventricle dose-dependently enhances the depth of isoflurane anesthesia, which might be caused by inhibition of neuronal nicotinic acetylcholine receptor transmission in the cerebrum.	Pancuronium	12-23	cholinergic receptor nicotinic alpha 2 subunit	Rattus norvegicus	176-208
22486886-1	2012	OBJECTIVE: To quantify the dose of pancuronium required to obtain moderate neuromuscular blockade as monitored by acceleromyography (NMB(mod) : train-of-four count of <=2) as a part of a balanced anaesthetic protocol in pigs used in cardiovascular research.	Pancuronium	35-46	neuromedin B	Sus scrofa	133-136
22486886-12	2012	The median initial dose and rate of pancuronium required to achieve NMB(mod) were 0.10 (range 0.10-0.13) mg kg(-1) and 0.11 (range 0.10-0.21) mg kg(-1) hour(-1) , respectively.	Pancuronium	36-47	neuromedin B	Sus scrofa	68-71
22486886-14	2012	CONCLUSIONS AND CLINICAL RELEVANCE: These pancuronium doses can be used as a guideline to achieve NMB(mod) in pigs as part of a balanced anaesthetic protocol.	Pancuronium	42-53	neuromedin B	Sus scrofa	98-101
17588565-4	2007	These data indicate that vecuronium, gallamine and pancuronium interact with an allosteric site on the muscarinic M2 receptor (located on the heart) and this may explain some of their cardiac side effects.	Pancuronium	51-62	cholinergic receptor muscarinic 2	Homo sapiens	103-125
17385680-0	2007	A modification of the kinetic determination of pancuronium bromide based on its inhibitory effect on cholinesterase.	Pancuronium	47-66	butyrylcholinesterase	Homo sapiens	101-115
17385680-1	2007	A modification of the existing spectrophotometric kinetic method for the determination of pancuronium bromide (PCBr), based on pooled human serum cholinesterase (ChE, EC 3.1.1.8 acylcholine acylhydrolase) inhibition, was developed.	Pancuronium	111-115	butyrylcholinesterase	Homo sapiens	146-160
16804673-0	2006	Cholinesterase inhibition based determination of pancuronium bromide in biological samples.	Pancuronium	49-68	butyrylcholinesterase	Homo sapiens	0-14
16804673-1	2006	Pancuronium bromide (PCBr) inhibition effect on enzyme cholinesterase from pooled human serum (Che, EC 3.1.1.8 acylcholine acylhydrolase) was used for development of a spectrophotometric kinetic method for PCBr determination in human serum and urine.	Pancuronium	0-19	butyrylcholinesterase	Homo sapiens	55-69
16804673-1	2006	Pancuronium bromide (PCBr) inhibition effect on enzyme cholinesterase from pooled human serum (Che, EC 3.1.1.8 acylcholine acylhydrolase) was used for development of a spectrophotometric kinetic method for PCBr determination in human serum and urine.	Pancuronium	21-25	butyrylcholinesterase	Homo sapiens	55-69
16804673-1	2006	Pancuronium bromide (PCBr) inhibition effect on enzyme cholinesterase from pooled human serum (Che, EC 3.1.1.8 acylcholine acylhydrolase) was used for development of a spectrophotometric kinetic method for PCBr determination in human serum and urine.	Pancuronium	206-210	butyrylcholinesterase	Homo sapiens	55-69
15824913-1	2005	INTRODUCTION: Potentiation of mivacurium by low-dose pancuronium is mostly due to an inhibition of plasma butyryl cholinesterase (BchE) resulting in a decreased rate of hydrolysis of mivacurium.	Pancuronium	53-64	butyrylcholinesterase	Homo sapiens	106-128
15824913-1	2005	INTRODUCTION: Potentiation of mivacurium by low-dose pancuronium is mostly due to an inhibition of plasma butyryl cholinesterase (BchE) resulting in a decreased rate of hydrolysis of mivacurium.	Pancuronium	53-64	butyrylcholinesterase	Homo sapiens	130-134
12717125-8	2003	RESULTS: Plasma cholinesterase activity decreased by 26% in the pancuronium-mivacurium group 3 min after injection of pancuronium (P < 0.01) and returned to baseline values 30 min later; however, no significant variation was observed in the mivacurium group.	Pancuronium	64-75	butyrylcholinesterase	Homo sapiens	16-30